Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of VH4004280 Oral Formulations in Healthy Adults
NCT06168318Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Dec 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VH-4004280 in human immunodeficiency virus infection (HIV) (8 arms), sponsored by ViiV Healthcare. Primary endpoints: Area under the plasma concentration-time curve from time zero to infinity, Area under the plasma drug concentration-time curve from zero to the last quantifiable concentration and 2 more. Started Dec 2023; status: completed.
02
Drugs
VH-4004280
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06168318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168318.